AZYO Aziyo Biologics

Aziyo Biologics to Report Third Quarter 2022 Financial Results on November 14, 2022

Aziyo Biologics to Report Third Quarter 2022 Financial Results on November 14, 2022

SILVER SPRING, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced that it will release third quarter 2022 financial results after market close on Monday, November 14, 2022. Members of the Company’s management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

The conference call can be accessed using the following information:

Webcast:

U.S. Investors: 866-682-6100

International Investors: 862-298-0702

Conference ID: 13734285

Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Aziyo website at .

About Aziyo Biologics

Aziyo Biologics is a regenerative medicine company with a commercial portfolio of differentiated products focused on improving outcomes in patients undergoing a range of surgical procedures, primarily for implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit .

Investors:

Matt Ferguson

Aziyo Biologics, Inc.

 

Media:

Courtney Guyer

Aziyo Biologics, Inc.

 



EN
07/11/2022

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Participate in Upcoming Investor Conferences

Elutia to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: Cantor Global Healthcare ConferenceFormat: Fireside Chat and 1x1 MeetingsFireside Chat Date and Time: Thursday, September 4, 2025, 9:45 a.m. ETWebcast Link: H.C. Wainwright 27th Annual Global Inves...

August 27, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adopti...

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the preferred antibi...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Report Second Quarter 2025 Financial Results on Thursday, Au...

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following informati...

July 31, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medic...

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, has been awarded the Medical Device Innovator Award by the Washington Business Journal. This award recognizes Dr. Williams’ groundbreaking contributions to the medical device industry, particularly her leadership in the development and successful commercializatio...

July 31, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platfor...

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices — The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a new study describing the bioinductive effects of its antibiotic-eluting CIED biologic envelope in the . Researchers ...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch